Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 23;3(2):471-474.
doi: 10.1002/jha2.403. eCollection 2022 May.

REGEN-COV antibody combination in patients with lymphoproliferative malignancies and SARS-CoV-2 infection

Yotam Bronstein  1   2 , Irit Avivi  1 , Yael C Cohen  1 , Eugene Feigin  2 , Chava Perry  1 , Yair Herishanu  1
Affiliations

REGEN-COV antibody combination in patients with lymphoproliferative malignancies and SARS-CoV-2 infection

Yotam Bronstein et al. EJHaem. .

Abstract

Patients with lymphoproliferative diseases are at high risk for SARS-CoV-2-related complications and mortality. The role of casirivimab and imdevimab (REGEN-COV), a neutralizing antibody cocktail, to treat immunocompromised hemato-oncological patients with SARS-CoV-2 disease 2019 (Covid-19) remains unknown. Here, we present our clinical experience on the outcome of 15 hematological patients treated with REGEN-COV for SARS-CoV-2 infection. Most patients failed to respond or achieved low antibody titer after 2-3 doses of BNT162b2 mRNA vaccine. All patients experienced clinical improvement with no mortality within a median follow-up of 70 days. In conclusion, early administration of REGEN-COV to high-risk hematological patients may prevent clinical deterioration and mortality from SARS-CoV-2 infection. The effectiveness of neutralizing antibodies may vary depending on the virus variants and in particular with the omicron variant (B.1.1.529).

Keywords: Covid‐19; REGEN‐COV; SARS‐Cov‐2; lymphoproliferative malignancies.

PubMed Disclaimer

References

    1. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients. Blood. 2020;136(25):2881–92. - PMC - PubMed
    1. Herzog Tzarfati K, Gutwein O, Apel A, Rahimi‐Levene N, Sadovnik M, Harel L, et al. BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021;96(10):1195–203. - PMC - PubMed
    1. Mittelman M, Magen O, Barda N, Dagan N, Oster HS, Leader A, et al. Effectiveness of the BNT162b2mRNA Covid‐19 vaccine in patients with hematological neoplasms. Blood. 2021. Online ahead of print. - PMC - PubMed
    1. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN‐COV2, a neutralizing antibody cocktail, in outpatients with Covid‐19. N Engl J Med. 2021;384(3):238‐51. - PMC - PubMed
    1. Coronavirus (COVID‐19) update: FDA authorizes monoclonal antibodies for treatment of COVID‐19. November 21, 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19...